B-Cancer	0	5	Tumor	Tumor	NN	B-NP
O	6	18	Angiogenesis	Angiogenesis	NN	I-NP
O	18	19	:	:	:	O
O	20	30	Initiation	Initiation	NN	B-NP
O	31	34	and	and	CC	I-NP
O	35	44	Targeting	Targeting	NN	I-NP
O	45	46	-	-	HYPH	B-NP
O	47	58	Therapeutic	Therapeutic	JJ	I-NP
O	59	68	Targeting	Targeting	NN	I-NP
O	69	71	of	of	IN	B-PP
O	72	74	an	an	DT	B-NP
O	75	78	FGF	FGF	NN	I-NP
O	78	79	-	-	HYPH	I-NP
O	79	86	Binding	Binding	NN	I-NP
O	87	94	Protein	Protein	NN	I-NP
O	94	95	,	,	,	O
O	96	98	an	an	DT	B-NP
O	99	109	Angiogenic	Angiogenic	JJ	I-NP
O	110	116	Switch	Switch	NNP	I-NP
O	117	125	Molecule	Molecule	NNP	I-NP
O	125	126	,	,	,	O
O	127	130	and	and	CC	O
O	131	140	Indicator	Indicator	NN	B-NP
O	141	143	of	of	IN	B-PP
O	144	149	Early	Early	JJ	B-NP
O	150	156	Stages	Stage	NNS	I-NP
O	157	159	of	of	IN	B-PP
B-Cancer	160	176	Gastrointestinal	Gastrointestinal	JJ	B-NP
I-Cancer	177	192	Adenocarcinomas	Adenocarcinoma	NNS	I-NP
O	193	194	-	-	HYPH	B-ADJP
O	194	195	.	.	.	O

B-Cancer	196	201	Tumor	Tumor	NN	B-NP
O	202	214	angiogenesis	angiogenesis	NN	I-NP
O	215	218	has	have	VBZ	B-VP
O	219	223	been	be	VBN	I-VP
O	224	231	related	relate	VBN	I-VP
O	232	234	to	to	TO	B-PP
O	235	238	the	the	DT	B-NP
O	239	249	initiation	initiation	NN	I-NP
O	250	252	as	as	RB	B-CONJP
O	253	257	well	well	RB	I-CONJP
O	258	260	as	as	IN	I-CONJP
O	261	272	progression	progression	NN	B-NP
O	273	279	toward	toward	IN	B-PP
O	280	284	more	more	RBR	B-NP
O	285	295	aggressive	aggressive	JJ	I-NP
O	296	304	behavior	behavior	NN	I-NP
O	305	307	of	of	IN	B-PP
O	308	313	human	human	JJ	B-NP
B-Cancer	314	320	tumors	tumor	NNS	I-NP
O	320	321	.	.	.	O

O	322	324	In	In	IN	B-PP
O	325	335	particular	particular	JJ	B-NP
O	335	336	,	,	,	O
O	337	340	the	the	DT	B-NP
O	341	349	activity	activity	NN	I-NP
O	350	352	of	of	IN	B-PP
O	353	363	angiogenic	angiogenic	JJ	B-NP
O	364	371	factors	factor	NNS	I-NP
O	372	374	is	be	VBZ	B-VP
O	375	382	crucial	crucial	JJ	B-ADJP
O	383	386	for	for	IN	B-PP
B-Cancer	387	392	tumor	tumor	NN	B-NP
O	393	404	progression	progression	NN	I-NP
O	404	405	.	.	.	O

O	406	408	We	We	PRP	B-NP
O	409	419	previously	previously	RB	B-ADVP
O	420	433	characterized	characterize	VBD	B-VP
O	434	435	a	a	DT	B-NP
O	436	444	secreted	secrete	VBN	I-NP
O	445	455	fibroblast	fibroblast	NN	I-NP
O	456	462	growth	growth	NN	I-NP
O	463	469	factor	factor	NN	I-NP
O	469	470	-	-	HYPH	O
O	470	477	binding	bind	VBG	B-VP
O	478	485	protein	protein	NN	B-NP
O	486	487	(	(	(	O
O	487	490	FGF	FGF	NN	B-NP
O	490	491	-	-	HYPH	B-NP
O	491	493	BP	BP	NN	I-NP
O	493	494	)	)	)	O
O	495	497	as	as	IN	B-PP
O	498	499	a	a	DT	B-NP
O	500	509	chaperone	chaperone	NN	I-NP
O	510	518	molecule	molecule	NN	I-NP
O	518	519	,	,	,	O
O	520	525	which	which	WDT	B-NP
O	526	531	binds	bind	VBZ	B-VP
O	532	534	to	to	TO	B-PP
O	535	542	various	various	JJ	B-NP
O	543	547	FGFs	FGF	NNS	I-NP
O	547	548	,	,	,	O
O	549	557	enhances	enhance	VBZ	B-VP
O	558	561	FGF	FGF	NN	B-NP
O	561	562	-	-	HYPH	B-NP
O	562	570	mediated	mediate	VBN	I-NP
O	571	582	biochemical	biochemical	JJ	I-NP
O	583	586	and	and	CC	I-NP
O	587	595	biologic	biologic	JJ	I-NP
O	596	602	events	event	NNS	I-NP
O	603	606	and	and	CC	O
O	607	618	importantly	importantly	RB	B-VP
O	619	621	is	be	VBZ	I-VP
O	622	623	a	a	DT	B-NP
O	624	631	crucial	crucial	JJ	I-NP
O	632	636	rate	rate	NN	I-NP
O	636	637	-	-	HYPH	O
O	637	645	limiting	limit	VBG	B-VP
O	646	652	factor	factor	NN	B-NP
O	653	656	for	for	IN	B-PP
B-Cancer	657	662	tumor	tumor	NN	B-NP
O	662	663	-	-	HYPH	B-NP
O	663	672	dependent	dependent	JJ	I-NP
O	673	685	angiogenesis	angiogenesis	NN	I-NP
O	685	686	.	.	.	O

O	687	689	We	We	PRP	B-NP
O	690	699	generated	generate	VBD	B-VP
O	700	710	monoclonal	monoclonal	JJ	B-NP
O	711	721	antibodies	antibody	NNS	I-NP
O	722	726	that	that	WDT	B-NP
O	727	733	target	target	VBP	B-VP
O	734	737	FGF	FGF	NN	B-NP
O	737	738	-	-	HYPH	O
O	738	740	BP	BP	NN	B-NP
O	741	748	protein	protein	NN	I-NP
O	749	752	and	and	CC	O
O	753	757	used	use	VBD	B-VP
O	758	762	them	them	PRP	B-NP
O	763	765	as	as	IN	B-PP
O	766	767	a	a	DT	B-NP
O	768	772	tool	tool	NN	I-NP
O	773	775	to	to	TO	B-VP
O	776	784	evaluate	evaluate	VB	I-VP
O	785	794	frequency	frequency	NN	B-NP
O	795	798	and	and	CC	I-NP
O	799	806	pattern	pattern	NN	I-NP
O	807	809	of	of	IN	B-PP
O	810	813	FGF	FGF	NN	B-NP
O	813	814	-	-	HYPH	B-NP
O	814	816	BP	BP	NN	I-NP
O	817	827	expression	expression	NN	I-NP
O	828	834	during	during	IN	B-PP
O	835	838	the	the	DT	B-NP
O	839	848	malignant	malignant	JJ	I-NP
O	849	860	progression	progression	NN	I-NP
O	861	863	of	of	IN	B-PP
B-Cancer	864	872	pancreas	pancreas	NN	B-NP
O	873	876	and	and	CC	O
B-Cancer	877	887	colorectal	colorectal	JJ	B-NP
I-Cancer	888	897	carcinoma	carcinoma	NN	I-NP
O	898	900	in	in	IN	B-PP
O	901	909	archival	archival	JJ	B-NP
B-Tissue	910	916	tissue	tissue	NN	I-NP
I-Tissue	917	924	samples	sample	NNS	I-NP
O	924	925	.	.	.	O

O	926	928	We	We	PRP	B-NP
O	929	934	found	find	VBD	B-VP
O	935	939	that	that	IN	B-SBAR
O	940	943	FGF	FGF	NN	B-NP
O	943	944	-	-	HYPH	B-NP
O	944	946	BP	BP	NN	I-NP
O	947	949	is	be	VBZ	B-VP
O	950	962	dramatically	dramatically	RB	I-VP
O	963	974	upregulated	upregulate	VBN	I-VP
O	975	981	during	during	IN	B-PP
O	982	985	the	the	DT	B-NP
O	986	996	initiation	initiation	NN	I-NP
O	997	999	of	of	IN	B-PP
B-Cancer	1000	1010	colorectal	colorectal	JJ	B-NP
O	1011	1014	and	and	CC	I-NP
B-Cancer	1015	1025	pancreatic	pancreatic	JJ	I-NP
I-Cancer	1026	1040	adenocarcinoma	adenocarcinoma	NN	I-NP
O	1040	1041	.	.	.	O

O	1042	1049	Crucial	Crucial	JJ	B-NP
O	1050	1057	genetic	genetic	JJ	I-NP
O	1058	1064	events	event	NNS	I-NP
O	1065	1075	underlying	underlie	VBG	B-VP
O	1076	1079	the	the	DT	B-NP
O	1080	1090	initiation	initiation	NN	I-NP
O	1091	1094	and	and	CC	I-NP
O	1095	1106	progression	progression	NN	I-NP
O	1107	1109	of	of	IN	B-PP
B-Cancer	1110	1120	colorectal	colorectal	JJ	B-NP
O	1121	1124	and	and	CC	I-NP
B-Cancer	1125	1135	pancreatic	pancreatic	JJ	I-NP
I-Cancer	1136	1150	adenocarcinoma	adenocarcinoma	NN	I-NP
O	1151	1155	with	with	IN	B-PP
O	1156	1157	a	a	DT	B-NP
O	1158	1168	particular	particular	JJ	I-NP
O	1169	1174	focus	focus	NN	I-NP
O	1175	1177	on	on	IN	B-PP
O	1178	1181	the	the	DT	B-NP
O	1182	1192	modulation	modulation	NN	I-NP
O	1193	1195	of	of	IN	B-PP
O	1196	1208	angiogenesis	angiogenesis	NN	B-NP
O	1209	1212	and	and	CC	O
O	1213	1227	antiangiogenic	antiangiogenic	JJ	B-NP
O	1228	1237	therapies	therapy	NNS	I-NP
O	1238	1241	are	be	VBP	B-VP
O	1242	1251	discussed	discuss	VBN	I-VP
O	1251	1252	.	.	.	O

O	1253	1255	We	We	PRP	B-NP
O	1256	1263	propose	propose	VBP	B-VP
O	1264	1268	that	that	IN	B-SBAR
O	1269	1272	the	the	DT	B-NP
O	1273	1285	upregulation	upregulation	NN	I-NP
O	1286	1288	of	of	IN	B-PP
O	1289	1292	the	the	DT	B-NP
O	1293	1301	secreted	secrete	VBN	I-NP
O	1302	1305	FGF	FGF	NN	I-NP
O	1305	1306	-	-	HYPH	I-NP
O	1306	1308	BP	BP	NN	I-NP
O	1309	1316	protein	protein	NN	I-NP
O	1317	1323	during	during	IN	B-PP
O	1324	1329	early	early	JJ	B-NP
O	1330	1336	phases	phase	NNS	I-NP
O	1337	1339	of	of	IN	B-PP
B-Cancer	1340	1348	pancreas	pancreas	NN	B-NP
O	1349	1352	and	and	CC	O
B-Cancer	1353	1358	colon	colon	NN	B-NP
I-Cancer	1359	1365	cancer	cancer	NN	I-NP
O	1366	1371	could	could	MD	B-VP
O	1372	1376	make	make	VB	I-VP
O	1377	1381	this	this	DT	B-NP
O	1382	1389	protein	protein	NN	I-NP
O	1390	1391	a	a	DT	B-NP
O	1392	1400	possible	possible	JJ	I-NP
B-Organism_substance	1401	1406	serum	serum	NN	I-NP
O	1407	1413	marker	marker	NN	I-NP
O	1414	1424	indicating	indicate	VBG	B-VP
O	1425	1428	the	the	DT	B-NP
O	1429	1437	presence	presence	NN	I-NP
O	1438	1440	of	of	IN	B-PP
O	1441	1445	high	high	JJ	B-NP
O	1445	1446	-	-	HYPH	I-NP
O	1446	1450	risk	risk	NN	I-NP
B-Pathological_formation	1451	1463	premalignant	premalignant	JJ	I-NP
I-Pathological_formation	1464	1471	lesions	lesion	NNS	I-NP
O	1471	1472	.	.	.	O

O	1473	1484	Furthermore	Furthermore	RB	B-ADVP
O	1484	1485	,	,	,	O
O	1486	1489	the	the	DT	B-NP
O	1490	1500	biological	biological	JJ	I-NP
O	1501	1509	activity	activity	NN	I-NP
O	1510	1512	of	of	IN	B-PP
O	1513	1516	FGF	FGF	NN	B-NP
O	1516	1517	-	-	HYPH	B-NP
O	1517	1519	BP	BP	NN	I-NP
O	1520	1522	is	be	VBZ	B-VP
O	1523	1534	neutralized	neutralize	VBN	I-VP
O	1535	1537	by	by	IN	B-PP
O	1538	1548	monoclonal	monoclonal	JJ	B-NP
O	1549	1559	antibodies	antibody	NNS	I-NP
O	1560	1570	suggesting	suggest	VBG	B-VP
O	1571	1574	the	the	DT	B-NP
O	1575	1584	potential	potential	NN	I-NP
O	1585	1588	for	for	IN	B-PP
O	1589	1597	antibody	antibody	NN	B-NP
O	1597	1598	-	-	HYPH	O
O	1598	1603	based	base	VBN	B-VP
O	1604	1615	therapeutic	therapeutic	JJ	B-NP
O	1616	1625	targeting	targeting	NN	I-NP
O	1625	1626	.	.	.	O

